GoodRx (NASDAQ:GDRX) is one of the top penny stocks to buy in investors’ stock portfolio. On May 27, GoodRx (NASDAQ:GDRX) affirmed its commitment to offering free and low-cost generic medications to the public.
The company launched GoodRx Companion, a new $14.99-a-month subscription service that helps consumers save on routine healthcare costs. The service combines lower drug prices with more affordable access to care and services. The service is tailored for patients managing chronic conditions who take multiple medications.
GoodRx Companion offers prescription savings on more than 200 common generic medications, as well as savings on cleanings, exams, X-rays, crowns, and other dental services. The service will also charge $19 on telehealth visits for common needs such as UTIs, skin care, flu, and other conditions.
The launch of Companion affirms GoodRx’s subscription strategy while creating another recurring revenue base. The subscription service also enables the company to engage consumers beyond individual prescription transactions.
GoodRx Holdings, Inc. (NASDAQ:GDRX) is a free digital platform and mobile app that helps Americans compare prescription medication prices and provides discount coupons to use at pharmacies nationwide. It functions primarily as a search engine for drug prices, allowing users to save money whether they are uninsured, underinsured, or have high insurance deductibles.
While we acknowledge the potential of GDRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: Top 10 Small Cap Stocks With Huge Growth Potential and Renaissance Technologies Returns, AUM, CEO and Top 10 Semiconductor Stock Picks.
Disclosure: None. Follow Insider Monkey on Google News.